Numinus ' revenue increased 240% year-over-year to $0.8 million in Q2 2022, primarily due to the Mindspace and Toronto Neurology Center acquisitions. On March 30, atai Life Sciences N.V. ( NASDAQ: ATAI ) reported fourth-quarter and full-year 2021 financial results and R&D progress. The clinical-stage biopharma company also highlighted strategic areas of its innovative mental health platform. atai Life Sciences expects at least 14 drug and enabling technology development catalysts over the next two years, and Phase 2a proof-of-concept topline data from PCN-101 in TRD. atai also expects further advancements in its patient support technologies and precision approaches to mental health. Alongside its R&D activities, atai launched its philanthropic arm, atai Impact, in October 2021. The company ended 2021 with a strong cash position of $362 million.